VC Mission Bay Capital Launches New Bio/Eco Tech Fund

Want to share this story?

A third fund was launched by San Francisco based Mission Bay Capital, a firm with experience in investing in medical and environmental startups.

The $60 million the Fund III received comes from several investors including Astellas Venture Management (the VC arm of global phama giant Astellas Pharma Inc.) Banyan Pacific Capital, Eli Lilly and Co., UC Investments, Mayfield, Wilson Sonsini Goodrich & Rosati and Zambon.

“We are thrilled to have a fresh pool of capital to invest into promising young companies,” said Douglas Crawford, Managing Director of the new fund in a statement. “The more than doubling of our fund from $25 million in Fund II to $60 million in Fund III is aligned with the expansion of our incubators in San Carlos and the addition of experienced bio-entrepreneur Robert Blazej to our management team. Alongside our new and returning investors, we look forward to supporting even more exciting early-stage biotechs.”

Mission Bay Capital, which invests in early-stage life-science tech startups, incubates its startups while it invests in them. Through its MBC BioLabs, early-stage biotechs are raised to successful outcomes. With state-of-the-art equipment, a vibrant community and a la carte business services, Mission Bay Capital enables and empowers entrepreneurial scientists to perform their research fast, frugal, and focused.

MBC BioLabs has successfully launched 138 companies, which have collectively raised over $3.5 billion since it began in 2013.